Global Gluten-Free Food Market Size, Share & Forecast, By Product Type, Customer Type & Distribution Channel, 2026–2031

The Global Gluten-Free Food Market was valued at USD 8,120 million in 2025. This base-year estimate covers packaged foods specifically formulated, certified, or marketed as gluten-free across bakery, snacks, pasta, pizza, and specialized foods. It excludes beverages, supplements, foodservice-only revenue, and naturally gluten-free products without an explicit gluten-free positioning. North America represented the largest regional pool at USD 4,200 million, supported by mature labeling rules, high diagnosis awareness, and broad retail availability. The scope is aligned with the category definition reported by.

The market is forecast to reach USD 14,127 million by 2031, expanding at a 9.73% CAGR over 2026-2031. Growth will be sustained by wider diagnosis, persistent wellness-led trial, improved product texture, faster online assortment expansion, and greater availability in mainstream convenience and supermarket channels. The annual market value is modeled to rise from USD 8,880 million in 2026 to USD 12,874 million in 2030 before reaching the 2031 endpoint. This trajectory extends the reported 2026 category base and forecast growth pattern from.

The profit pool is shifting toward premium bakery, convenient snacks, specialty nutrition, and digitally discoverable assortments rather than basic replacement products alone. Bakery remains the largest product category, accounting for 44.59% of the market in 2026, while online retail is expected to be the fastest-growing channel through 2031. Specialist retailers also retain attractive value because they aggregate certified, allergen-aware, and emerging-brand portfolios that mass merchants may not stock deeply. Manufacturers that improve taste and shelf life while preserving certification can defend higher realized pricing and repeat purchase.

Affordability and cross-contact control are the two most material constraints. Gluten-free products often carry a meaningful price premium because of specialized ingredients, segregated processing, smaller production runs, laboratory testing, and certification expenses. In the United Kingdom, gluten-free groceries were reported at up to 35% more than standard equivalents, restricting household basket expansion. Compliance failures also damage trust: an India study found 10.1% of 794 tested products exceeded 20 mg/kg gluten. Companies therefore need rigorous supplier qualification, dedicated lines, validated cleaning, and recurring testing.

North America leads with USD 4,200 million in 2025, equal to 51.69% of global revenue, and remains the strongest near-term commercialization market. Europe follows at USD 1,940 million, supported by established claims regulation and a substantial diagnosed population. Asia Pacific, at USD 1,320 million, offers the strongest structural runway as modern retail, diagnosis, urban incomes, and product localization improve. Latin America and the Middle East and Africa remain smaller at USD 340 million and USD 320 million respectively, but selective urban markets can support premium specialist formats.

The most durable demand driver is medically necessary avoidance among people with celiac disease, non-celiac gluten sensitivity, and wheat allergy, supplemented by a larger wellness-oriented consumer group. A global meta-analysis estimated celiac seroprevalence at 1.4% and biopsy-confirmed prevalence at 0.7%, creating a recurring need for safe, trusted substitutes rather than occasional discretionary purchases. Diagnosis remains underdeveloped in many countries, so improved testing and clinician awareness can expand the addressable base. For manufacturers, certification credibility and dependable availability are therefore more defensible than short-lived dietary fashion alone.

Companies should compete through a combined certification, sensory quality, scale, and channel strategy. First, they must protect trust with controlled sourcing, segregated production, validated testing, and transparent labeling. Second, formulation investment should target texture, freshness, protein, fiber, and clean-label performance to narrow the quality gap with conventional foods. Third, portfolios should balance mass-retail staples with premium, medical-grade, and online-exclusive products. Finally, regional localization matters because claim thresholds differ: the United States and European Union use a 20 ppm ceiling, while Australia requires no detectable gluten for a gluten-free claim.